Regenicin Inc. (RGIN) 0.0220 $RGIN Market Maker

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Regenicin Inc. (RGIN) 0.0220 $RGIN

Market Maker Surveillance Report. KND, INTC, MDR, CDNS, HTZ, RGIN, Highest Net Buy Volume With Lowest Price Friction For Thursday, November 20th 2014
M2 - Fri Nov 21, 3:16AM CST
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Thursday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Thursday there were 4485 companies with "abnormal" market making, 2789 companies with positive Friction Factors and 2000 companies with negative Friction Factors. Here is a list of the top companies with the highest net buy volume on Thursday and lowest price Friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. KINDRED HEALTHCARE, INC. (NYSE:KND), INTEL CORPORATION (NASDAQ:INTC), McDermott International Inc (NYSE:MDR), CADENCE DESIGN SYSTEMS, INC. (NASDAQ:CDNS), HERTZ GLOBAL HOLDINGS, INC. (NYSE:HTZ), Regenicin Inc (OTC:RGIN). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
KND: 22.76 (+0.30), MDR: 4.61 (-0.24), HTZ: 20.60 (+1.04), CDNS: 19.20 (-0.06), INTC: 32.99 (+0.02)

Regenicin Enters Into Asset Purchase Agreement with Amarantus Bioscience Holdings, Inc.
PR Newswire - Wed Nov 19, 11:46AM CST
Regenicin, Inc. (OTC Bulletin Board: RGIN) a biotechnology company specializing in the development of and commercialization of regenerative cell therapies to restore the health of damaged tissues and organs, announced today that it has entered into an Asset Purchase Agreement with Amarantus Bioscience Holdings, Inc. ("Amarantus" . Under the agreement, Amarantus acquires Regenicin rights and claims in the company's litigation currently pending against Lonza Walkersville and Lonza America, Inc. This included all of Regenicin's Cutanagen intellectual property rights and any Lonza manufacturing know-how technology Regenicin may have. In addition, Regencin will sell to Amarantus its PermaDerm trademark and related intellectual property rights associated with it.

Amarantus Enters Into Exclusive Option Agreement to Acquire Engineered Skin Substitute for the Treatment of Severe Burns From Lonza
Thomson Reuters ONE - Mon Nov 17, 3:20PM CST
- Engineered Skin substitute (ESS): Phase 1/ Early Phase 2 product candidate that has potential to be a revolutionary new treatment for severe burns

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Faith and Resilience in China: The Legacy of the Long March

Updated Category News Views 5

History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...

Continue Reading
ASTS Faces a Legal Countdown – Investors Take Note

Updated Category News Views 3

AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...

Continue Reading
UEG's New Advisory Board: Elevating Patient Voices

Updated Category News Views 6

Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...

Continue Reading
AEVEX Faces 48-Hour Deadline for Investor Class Action

Updated Category News Views 4

Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....

Continue Reading
Tomorrowland's Shanghai Return: An Electri-Lifesaver

Updated Category News Views 5

You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...

Continue Reading
Antheia Secures $80M for Critical Medicine Onshoring

Updated Category News Views 9

Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...

Continue Reading
Lundbeck's Board Leadership Transitions into New Era

Updated Category News Views 3

A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...

Continue Reading

Top 5 Most Recently Viewed Articles

Huggies and Walgreens Uniting to Tackle Diaper Need

Updated Category News Views 300

Partnering to Tackle Diaper Needs Huggies and Walgreens are thrilled to kick off a meaningful initiative designed to support families dealing with diaper need. For each pack of Huggies Diapers bought at Walgreens, either in stores or online, Huggies will donate a day's worth of diapers to the National Diaper Bank Network, aiming to contribute as many as one million...

Continue Reading
Surging Growth of Fatty Methyl Ester Sulfonate Market By 2033

Updated Category News Views 144

Exploring the Future of the Fatty Methyl Ester Sulfonate Market The dynamic world of the fatty methyl ester sulfonate (FMES) market is entering an exciting phase of growth. Beginning at an estimated value of US$ 805.9 million in 2024, the forecast projects the market to surge to US$ 2,095.1 million by 2033. This impressive leap represents an annual growth rate of 11.20%,...

Continue Reading
Biden Administration Approves Perpetua's Mining Project

Updated Category News Views 151

Biden Administration Approves Perpetua's Mining Project In a significant move for resource management and economic development, the Biden administration has granted the final mining permit for Perpetua Resources' antimony and gold mine located in Idaho. This decision comes in response to concerns regarding China's substantial control over the global market for antimony, a...

Continue Reading
Neurocrine Biosciences Set to Share Q2 2025 Financial Insights

Updated Category News Views 130

Neurocrine Biosciences Announces Upcoming Financial Conference Call Neurocrine Biosciences, Inc. (NASDAQ: NBIX), a leader in the field of neuroscience, is excited to inform stakeholders about its scheduled conference call and webcast. The event is set for the afternoon of July 30, where financial results for the second quarter of 2025 will be shared. This moment allows...

Continue Reading
Societe Generale Updates on Universal Registration Document

Updated Category News Views 127

Introducing the Second Amendment Societe Generale has exciting news regarding the second amendment to its 2025 Universal Registration Document. This essential document plays a crucial role in ensuring transparency and compliance with regulatory frameworks. The amendment was officially filed with the French Financial Markets Authority (AMF), ensuring that all stakeholders...

Continue Reading